Bixalomer

PreclinicalSmall molecule

Astellas

Bixalomer is one of 51 small molecule programs targeting Hyperphosphatemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperphosphatemiaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

HyperphosphatemiaPreclinical

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

172 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

17 2

Uloric

Takeda

Preclinical

2 3

Sovaldi

Gilead

Preclinical

1 4

Glucotrol

Pfizer

Preclinical

1 5

Vemlidy

Gilead

Preclinical

1 6

Lorelco

Sanofi

Preclinical

1 7

Activase

Flomax

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

PROCRIT

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease1 trial

Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease

Completed· Astellas logo

Astellas··NCT02805348·144 enrolled

Hyperphosphatemia1 trial

Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis

Completed· Astellas logo

Astellas··NCT01903213·123 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Bixalomer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bixalomer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bixalomer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Astellas

Bixalomer

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease1 trial

Hyperphosphatemia1 trial

References

Drug Info

Quick Facts

Related News